Cordasco Financial Network continued to hold its position in Astrazeneca PLC (NYSE:AZN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,668 shares of the company’s stock at the end of the second quarter. Cordasco Financial Network’s holdings in Astrazeneca PLC were worth $141,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. First Niagara Bank bought a new stake in shares of Astrazeneca PLC during the second quarter worth $314,000. Sigma Planning Corp bought a new stake in shares of Astrazeneca PLC during the second quarter worth $523,000. CIBC World Markets Inc. bought a new stake in shares of Astrazeneca PLC during the second quarter worth $1,063,000. Checchi Capital Advisers LLC raised its stake in shares of Astrazeneca PLC by 3.1% in the second quarter. Checchi Capital Advisers LLC now owns 21,871 shares of the company’s stock worth $660,000 after buying an additional 663 shares in the last quarter. Finally, Bollard Group LLC raised its stake in shares of Astrazeneca PLC by 5.1% in the second quarter. Bollard Group LLC now owns 42,023 shares of the company’s stock worth $1,269,000 after buying an additional 2,050 shares in the last quarter. 11.71% of the stock is owned by hedge funds and other institutional investors.
Astrazeneca PLC (NYSE:AZN) traded down 0.89% during mid-day trading on Monday, hitting $33.52. 3,330,061 shares of the company traded hands. The company’s 50-day moving average is $33.49 and its 200-day moving average is $30.37. Astrazeneca PLC has a one year low of $26.97 and a one year high of $35.04. The stock has a market capitalization of $84.81 billion, a price-to-earnings ratio of 38.31 and a beta of 0.77.
Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The firm had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.56 billion. During the same period last year, the company posted $1.21 EPS. The business’s quarterly revenue was down 4.0% on a year-over-year basis. Analysts predict that Astrazeneca PLC will post $2.97 EPS for the current year.
The firm also recently disclosed a dividend, which was paid on Monday, September 12th. Stockholders of record on Friday, August 12th were issued a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 78.29%.
AZN has been the topic of a number of research reports. Deutsche Bank AG reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Tuesday, June 7th. Citigroup Inc. reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, May 25th. Bank of America Corp. reiterated a “buy” rating and issued a $36.65 target price on shares of Astrazeneca PLC in a report on Monday, July 18th. TheStreet upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Friday, July 22nd. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Thursday, July 28th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have given a buy rating and three have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $37.49.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.